| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7988001 (Pediatric) | BOEHRINGER INGELHEIM | Container provided with a pressure equalization opening |
Feb, 2022
(1 year, 7 months ago) | |
| US7284474 | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Aug, 2024
(10 months from now) | |
|
US7284474 (Pediatric) | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Feb, 2025
(1 year, 4 months from now) | |
| US7896264 | BOEHRINGER INGELHEIM | Microstructured high pressure nozzle with built-in filter function |
May, 2025
(1 year, 7 months from now) | |
|
US7896264 (Pediatric) | BOEHRINGER INGELHEIM | Microstructured high pressure nozzle with built-in filter function |
Nov, 2025
(2 years from now) | |
| US7396341 | BOEHRINGER INGELHEIM | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
Oct, 2026
(3 years from now) | |
| US9027967 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2027
(3 years from now) | |
|
US7396341 (Pediatric) | BOEHRINGER INGELHEIM | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
Apr, 2027
(3 years from now) | |
|
US9027967 (Pediatric) | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Oct, 2027
(4 years from now) | |
| US7837235 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2028
(4 years from now) | |
|
US7837235 (Pediatric) | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Sep, 2028
(4 years from now) | |
| US8733341 | BOEHRINGER INGELHEIM | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
Oct, 2030
(7 years from now) | |
|
US8733341 (Pediatric) | BOEHRINGER INGELHEIM | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
Apr, 2031
(7 years from now) | |
Spiriva Respimat is owned by Boehringer Ingelheim.
Spiriva Respimat contains Tiotropium Bromide.
Spiriva Respimat has a total of 13 drug patents out of which 1 drug patent has expired.
Expired drug patents of Spiriva Respimat are:
- US7988001*PED
Spiriva Respimat was authorised for market use on 24 September, 2014.
Spiriva Respimat is available in spray, metered;inhalation dosage forms.
The generics of Spiriva Respimat are possible to be released after 16 April, 2031.
Drugs and Companies using TIOTROPIUM BROMIDE ingredient
Market Authorisation Date: 24 September, 2014
Treatment: NA
Dosage: SPRAY, METERED;INHALATION
SPIRIVA RESPIMAT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic